Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (21-30 of 459) with videos related to

Pageof 46
Sort By:
Immunotherapy|April 13, 2022
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Cancer Treatment Reviews|September 2, 2017
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035)Francesca Tartari, Matteo Santoni, Mirco Pistelli, et al.
Future Oncology (London, England)|February 16, 2021
A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?Francesco Massari, Alessandro Rizzo, Veronica Mollica, et al.
European Urology|November 5, 2018
Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell CarcinomaMatteo Santoni, Rodolfo Montironi, Nicola Battelli, et al.
Journal of Clinical Medicine|November 27, 2021
Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic RevolutionAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Cancer Treatment Reviews|January 12, 2025
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinomaMatteo Santoni, Veronica Mollica, Alessandro Rizzo, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|May 1, 2021
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophagesMatteo Santoni, Francesco Massari, Rodolfo Montironi, et al.
Targeted Oncology|May 11, 2019
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable MicrobesMelissa Bersanelli, Matteo Santoni, Andrea Ticinesi, et al.
Clinical Genitourinary Cancer|July 20, 2022
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database AnalysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Clinical Medicine Insights. Oncology|March 3, 2025
Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial CancerAdriana Guarino, Matteo Santoni, Martina Catalano, et al.
Pageof 46

Showing results (21-30 of 459) with videos related to

Sort By:
Pageof 46
Immunotherapy|April 13, 2022
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Cancer Treatment Reviews|September 2, 2017
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035)Francesca Tartari, Matteo Santoni, Mirco Pistelli, et al.
Future Oncology (London, England)|February 16, 2021
A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?Francesco Massari, Alessandro Rizzo, Veronica Mollica, et al.
European Urology|November 5, 2018
Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell CarcinomaMatteo Santoni, Rodolfo Montironi, Nicola Battelli, et al.
Journal of Clinical Medicine|November 27, 2021
Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic RevolutionAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Cancer Treatment Reviews|January 12, 2025
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinomaMatteo Santoni, Veronica Mollica, Alessandro Rizzo, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|May 1, 2021
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophagesMatteo Santoni, Francesco Massari, Rodolfo Montironi, et al.
Targeted Oncology|May 11, 2019
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable MicrobesMelissa Bersanelli, Matteo Santoni, Andrea Ticinesi, et al.
Clinical Genitourinary Cancer|July 20, 2022
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database AnalysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Clinical Medicine Insights. Oncology|March 3, 2025
Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial CancerAdriana Guarino, Matteo Santoni, Martina Catalano, et al.
Pageof 46